Silvia Villa1, Friederike Kendel2, Lionne Venderbos3, Tiziana Rancati1, Chris Bangma3, Peter Carroll4, Louis Denis5, Laurence Klotz6, Ida J Korfage3, Athene J Lane7, Tiziana Magnani1, Ken Mastris5, Antti Rannikko8, Monique Roobol3, Bruce Trock9, Roderick Van den Bergh10, Hendrik Van Poppel11, Riccardo Valdagni12, Lara Bellardita13. 1. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 2. Institut für Medizinische Psychologie, Berlin, Germany. 3. Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA. 5. Europa Uomo, Oncology Centre Antwerp, Antwerp, Belgium. 6. Sunnybrook Health Sciences Centre, Toronto, Canada. 7. School of Social and Community Medicine, University of Bristol, Bristol, UK. 8. Helsinki University Central Hospital, Helsinki, Finland. 9. Division of Epidemiology, Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. 10. University Medical Center Utrecht, Utrecht, The Netherlands. 11. University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium. 12. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Università di Milano, Milan, Italy. 13. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: lara.bellardita@istitutotumori.mi.it.
Abstract
BACKGROUND: Literature on the health-related quality of life (HRQoL) for men with localized prostate cancer (PCa) on active surveillance (AS) shows a need for methodological guidance regarding HRQoL issues and how to address them. OBJECTIVE: The European School of Oncology Task Force (ESO TF) aimed to identify a core set of research questions and related measures to include in AS HRQoL studies. DESIGN, SETTING, AND PARTICIPANTS: A modified Delphi study was used to reach consensus on AS HRQoL research topics and tools between 2014 and 2015. Data were collected by engaging a multidisciplinary team of 15 experts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: An open-ended questionnaire was used to collect information from ESO TF members regarding issues in AS HRQoL research. Then a structured questionnaire was used to collect ratings on the usefulness/importance of different AS HRQoL aspects. Items that ≥80% of ESO TF members rated as useful/important were retained. Items with a 50-80% rating were discussed to reach final agreement. RESULTS AND LIMITATIONS: Six main research questions concerning the selection of outcome measures, measurement tools, and comparison groups were identified as relevant. The core set of measures identified were related to individual characteristics, psychological dimensions; decision-making-related issues, and physical functioning. The multidisciplinary expertise of ESO TF members was a significant asset, even if bringing different backgrounds to the discussion table represented a challenge. CONCLUSIONS: HRQoL measures have to be sensitive to the specific needs of men on AS. The definition of HRQoL outcomes will enhance a broader understanding of the HRQoL of men on AS and sustain patient-centered medicine. PATIENT SUMMARY: An international panel agreed on a set of health-related quality-of-life aspects to be assessed among men on active surveillance for prostate cancer. Valid relevant questionnaires were identified. The experts' indications lay a foundation for future research and clinical practice.
BACKGROUND: Literature on the health-related quality of life (HRQoL) for men with localized prostate cancer (PCa) on active surveillance (AS) shows a need for methodological guidance regarding HRQoL issues and how to address them. OBJECTIVE: The European School of Oncology Task Force (ESO TF) aimed to identify a core set of research questions and related measures to include in AS HRQoL studies. DESIGN, SETTING, AND PARTICIPANTS: A modified Delphi study was used to reach consensus on AS HRQoL research topics and tools between 2014 and 2015. Data were collected by engaging a multidisciplinary team of 15 experts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: An open-ended questionnaire was used to collect information from ESO TF members regarding issues in AS HRQoL research. Then a structured questionnaire was used to collect ratings on the usefulness/importance of different AS HRQoL aspects. Items that ≥80% of ESO TF members rated as useful/important were retained. Items with a 50-80% rating were discussed to reach final agreement. RESULTS AND LIMITATIONS: Six main research questions concerning the selection of outcome measures, measurement tools, and comparison groups were identified as relevant. The core set of measures identified were related to individual characteristics, psychological dimensions; decision-making-related issues, and physical functioning. The multidisciplinary expertise of ESO TF members was a significant asset, even if bringing different backgrounds to the discussion table represented a challenge. CONCLUSIONS: HRQoL measures have to be sensitive to the specific needs of men on AS. The definition of HRQoL outcomes will enhance a broader understanding of the HRQoL of men on AS and sustain patient-centered medicine. PATIENT SUMMARY: An international panel agreed on a set of health-related quality-of-life aspects to be assessed among men on active surveillance for prostate cancer. Valid relevant questionnaires were identified. The experts' indications lay a foundation for future research and clinical practice.
Authors: Paola Dordoni; Fabio Badenchini; Maria Francesca Alvisi; Julia Menichetti; Letizia De Luca; Teresa Di Florio; Tiziana Magnani; Cristina Marenghi; Tiziana Rancati; Riccardo Valdagni; Lara Bellardita Journal: Support Care Cancer Date: 2020-05-18 Impact factor: 3.603